UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other jurisdiction of incorporation or organization) 900 Stewar ...

Corporate Presentation June 2024 Forward Looking Statements This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the "Company") nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Compan ...

Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Conference Call February 12, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Les Sulewski - Truist Yale Jen - Laidlaw & Company Sam Eiber - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon, and welcome, everyone, to the Beyond Air Financial Results Call for the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Securities registered pursuant to Sect ...

Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jeremy Jacoby - Truist Securities Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other j ...

Beyond Air, Inc. (NASDAQ:XAIR) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Marie Thibault - BTIG Scott Henry - ROTH Capital Jason Bednar - Piper Sandler Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Operator Good afternoon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other jurisd ...

Financial Data and Key Metrics Changes - Revenue for the fiscal year ended March 31, 2023, was zero, unchanged from the previous fiscal year, but management expressed confidence that this would be the last time they report zero revenue [82] - Selling, general and administrative expenses increased to $34.7 million from $18.4 million, primarily due to investments in Beyond Cancer and the U.S. commercial launch [83] - GAAP net loss for the fiscal year was $59.4 million, compared to a net loss of $43.2 million for the previous year, with a loss per share of $1.86 [92] Business Line Data and Key Metrics Changes - The company is in phase 2 of the commercial launch for LungFit PH, expanding its commercial team and aiming to increase market share [9][74] - The company has conducted over 150 in-person demonstrations of LungFit PH, receiving positive feedback and optimizing the system [73] - Management expects annual contract signings to be measured in the millions over the next six months [75] Market Data and Key Metrics Changes - The market for nitric oxide in hospitals is estimated to be around $350 million to $400 million, with approximately 1,000 hospitals as potential customers [45] - The company anticipates that the customer base and commercial function being established will support future launches of LungFit PRO [76] Company Strategy and Development Direction - The company is focusing on expanding its commercial operations and increasing its market share, with plans to grow its team over the next 18 to 24 months [106] - The company is preparing for a pivotal study for LungFit PRO in the first half of 2025 and a pilot study for LungFit GO in the second half of 2024 [84][69] - The company is also exploring new programs, including a focus on autism spectrum disorder through nNOS inhibitors [88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving CE Mark and FDA submission for LungFit PH, indicating a positive regulatory outlook [77] - The company is optimistic about the feedback from hospitals and the potential for future growth, emphasizing the importance of building a solid foundation during the initial phases of the commercial launch [72][75] - Management acknowledged supply chain challenges but noted improvements in training and logistics [101] Other Important Information - The company secured debt financing of up to $40 million, which is expected to strengthen its position for executing its strategy [70] - The company has completed multiple studies with no serious adverse events attributed to nitric oxide, reinforcing the safety of its products [85] Q&A Session Summary Question: What was accomplished in phase 1 of the LungFit PH launch? - Management indicated that several contracts were signed, and positive clinical feedback was received, setting a foundation for future growth [100][101] Question: How will the commercial sales force expand? - The company plans to expand its team to around 70 to 80 people over the next 18 to 24 months, including sales reps and clinical specialists [106] Question: What is the expected revenue from contracts? - Management stated that contracts are expected to convert into revenue gradually, with a slow build-up anticipated over the next several quarters [124]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other jurisdiction of incorporation or organization) 900 Stewar ...